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1.25 hospitalizations. Diagnostic tests were also more frequent (rectosigmoidoscopy: 
49.3%; abdominal echography: 43.6%) except thyroid function (70.0%). The annual 
cost of second line was € 2,114 [1,509;2,819] versus € 2,920 [2,072;3,917] after second 
line failure. Hospitalizations accounted for about 75% of the costs. ConClusions: 
IBS with constipation leads to significant resource use and high costs certainly in 
case of second line treatment failure.
Gastrointestinal DisorDers – Patient-reported outcomes & Patient  
Preference studies
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aGreement Between ChilD anD Parent symPtom Diary resPonses 
in ChroniC ConstiPation (CC) anD irritaBle Bowel synDrome with 
ConstiPation (iBs-C): imPliCations for the measurement of symPtoms 
in younG ChilDren
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objeCtives: Using patient-reported and observer-reported outcome measures to 
assess symptoms in children is challenging. While the child is arguably the most 
‘valid’ reporter, parents may provide more reliable responses. Our aim was to 
assess the agreement in child and parent ratings of CC/IBS-C symptoms collected 
through an electronic daily diary (eDiary). Methods: Separate child and parent 
eDiaries were developed to assess CC/IBS-C symptoms based on concept elicita-
tion interviews with 64 children and 75 parents. The eDiaries were completed by 
36 children (aged 6-11) and 30 parents for 5-9 days prior to cognitive debriefing 
interviews. eDiary data were compared for five symptoms: abdominal pain, bowel 
movement (BM) frequency, stool form/consistency, straining and rectal pain during 
defecation. Results: There were moderate to high levels of agreement (children/
parents selecting the same level of response on a given day) for all items, including 
66.9% agreement for BM frequency; 70.2% for stool form and 72.5% for rectal pain. 
Children’s reports of their ‘tummy hurting’ were consistent with parents seeing 
their child holding his/her tummy (68.5% agreement) and parents being told by the 
child that his/her tummy hurt (76.4% agreement). Children’s reports of straining 
were consistent with parents observing their child making a face (60.4% agree-
ment) and hearing their child grunt (52.3% agreement) during defecation. Across 
all symptoms, agreement was higher for 6-8 year old children and their parents 
(mean 76.9% agreement) compared to 9-11 year old children and their parents (mean 
58.4%). ConClusions: The results present evidence of moderate to strong agree-
ment between children’s and parents’ reports of core CC/IBS-C symptoms. Lower 
levels of agreement in ratings amongst 9-11 year old children and their parents may 
be due to parents being less aware of their child’s symptoms.
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ValiDatinG the uniDimensional fatiGue imPaCt sCale (u-fis) for use in 
Crohn’s Disease
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objeCtives: Fatigue is usually defined as a feeling of exhaustion, lack of energy 
or tiredness and affects many aspects of daily living. Crohn’s Disease (CD) is often 
associated with severe fatigue. The Fatigue Impact Scale (FIS) was developed to 
determine the mental and physical impacts of fatigue. It has been simplified and 
shortened to 22 items and shown by Rasch analysis to be unidimensional. This 
version is called the U-FIS. The study was designed to determine the validity of the 
U-FIS when used with CD patients. Methods: CD patients were asked to com-
plete the U-FIS and a subset of respondents completed it again two weeks later to 
assess test-retest reliability. Rasch analysis was applied to U-FIS data to determine 
unidimensionality. Construct validity was further assessed by relating scores on 
the U-FIS to those on the Crohn’s Life Impact Scale (CLIQ) and the Nottingham 
Health Profile (NHP). Results: A total of 158 CD patients (36.1% female; aged 16-79 
years (mean: 42.4; SD 15.0)) completed the U-FIS, with 103 completing it a second 
time. Overall fit to the Rasch model was confirmed (p = 0.61) and no items misfit. 
Internal consistency (0.98) and reproducibility (test-retest reliability = 0.88) for the 
U-FIS were good. U-FIS scores correlated 0.79 with those on the CLIQ indicating the 
importance of fatigue to quality of life. U-FIS scores were also related as expected 
with NHP section scores. ConClusions: The U-FIS is a reliable and valid instru-
ment for measuring fatigue in Crohn’s Disease. These findings replicate those found 
with the use of the measure with patients who have Multiple Sclerosis. The U-FIS 
is valuable as it provides a holistic index of the impact of fatigue from the patient’s 
perspective. The measure may prove valuable for use with patients who have a wide 
variety of chronic conditions.
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objeCtives: The study was designed to identify the final CLIQ – the first patient-
reported outcome measure specific to adults with Crohn’s Disease (CD) and deter-
mine its unidimensionality, reproducibility and construct validity. The measure has 
two scales; Activity limitations and needs-based Quality of Life (QoL). Methods: 
CD patients were sent a package consisting of the CLIQ, the Nottingham Health 
Profile (NHP), the Unidimensional Fatigue Impact Scale (U-FIS) and a demographic 
questionnaire. A subset of respondents received a second questionnaire package 
2 weeks later. Rasch analysis was applied to responses for item reduction and 
assessment of unidimensionality. Assessments of internal consistency, test-retest 
reliability and construct validity were also undertaken. Results: The CLIQ was 
completed by 273 CD patients (65.6% female; aged 16-79 years (mean: 43.9; SD 15.1). 
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objeCtives: To assess the cost-effectiveness of peginterferon α -2a and peginter-
feron α -2b in combination with ribavirin compared to best supportive care (BSC), for 
the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3 
to 17 years. Methods: A Markov state-transition economic model of chronic HCV 
in children and young people was developed that extrapolated the impact of sus-
tained virological response (SVR) on life expectancy, quality-adjusted life expectancy 
and lifetime costs. The model was adapted from one previously developed for adults. 
A systematic review was conducted of the clinical effectiveness of the treatments, 
and the health related quality of life for patients with hepatitis C. Uncertainty was 
explored through probabilistic and deterministic sensitivity analyses. Results: 
Seven studies were identified that were relatively small and of generally poor qual-
ity. Estimates of SVR were similar for peginterferon α -2a (60%) and peginterferon 
α -2b (58%), whilst the SVR for no treatment was assumed to be zero. From this 
model, peginterferon alfa (α -2a or α -2b) in combination with ribavirin was more 
effective and cheaper than BSC. Sensitivity analyses suggest that the results were 
generally robust to all changes to the structural assumptions and input parameters. 
The model results were most sensitive to changes to the discount rate, time hori-
zon, SVR and baseline fibrosis of the cohort. ConClusions: Treatment of children 
and young people with peginterferon alfa (α -2a or α -2b) and ribavirin may be an 
effective therapy. Peginterferon alfa (α -2a or α -2b) in combination with ribavirin is 
cost-effective compared with BSC. However, the available evidence is of poor quality. 
The views expressed in this paper are those of the authors and do not necessarily 
represent the views or policies of the UK HTA programme or Department of Health.
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objeCtives: To estimate the cost-effectiveness in Romanian setting of triple ther-
apy with Telaprevir and Peginterferon/Ribavirin (TVR+PR) compared with PR alone 
in previously untreated patients with hepatitis C virus (HCV) infection from the 
third payer - National Health Insurance Agency (NHIA). Methods: We used the 
published data of efficacy from large international trials and published Markov 
models to estimate the cost-effectiveness of this new HCV serine protease inhibi-
tor (telaprevir) using the specific local cost and epidemiological data. The superior 
results shown by Jacobson IM et all in ADVANCE trial - (Telaprevir for previously 
untreated chronic hepatitis C virus infection) for telaprevir - 75% sustained virologic 
response compared with 44% for PR alone. The discount rate was 3% for both cost 
and efficacy. Cost were extracted from NIHA tarrifs, Minister of Health drugs price 
catalog and from previous published data. The reference patient was a 45-year-old 
male with chronic liver disease due to chronic HCV infection. Time horizon was set 
patient life time. The clinical outcomes and Utilities for all health states were taken 
from ADVANCE phase-3 trial. The comparator was Peginterferon 2alfa with ribavirin. 
The effectiveness was measured in quality-adjusted life years (QALY).The cost of 
secondary drug reactions were not included in the model. Results: Incremental 
cost effectiveness ratio (ICER) for telaprevir in combination with PR compared to PR 
alone was 23291 € /1 gained QALY. ConClusions: As in Romania HTA is only at the 
beginning, health authorities has to evaluate the most cost-effective strategy to fol-
low for treatment of patients with chronic hepatitis as ICER of telaprevir in combina-
tion with PR compared with PR alone is reaching or is above the level recommended 
by Word Health Organisation as upper threshold (3 GDP/capita – Romania’s GDP/
capita is 6200Euro). Further CUA should be performed, including for guided therapy 
and treatment designated to previous treated patients.
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objeCtives: Patients suffering from irritable bowel syndrome (IBS) with constipa-
tion (IBS-C) receive laxatives as first line therapy. In spite of these laxatives most 
of them experience failure. We aimed at describing the current management and 
its costs of Belgian IBS-C patients who failed first line treatment. Methods: A 
2-round Delphi panel was conducted including general practitioners (GP) and 
gastroenterologists. The type and frequency of medical resources used per year 
as second-line IBS-C therapy (consultations, exams/tests, drugs, hospitalizations) 
were collected, reflecting the expert’s own practice in the first round and find-
ing a Belgian consensus in the second round. Two patients’ profiles were defined: 
second line current management and third line management in case of second 
line failure. Unit costs (2012 INAMI/RIZIV tariffs) were assigned to the resources 
used to calculate a cost per patient-year and a range based on the distribution of 
experts’ answers. Results: Eleven experts participated (6 GPs/5 gastroenterolo-
gists). The drugs prescribed in second line were laxatives (71.4%, mainly osmotics), 
spasmolytics (72.2%), pain killers (11.5%) and antidepressants (6.0%). There were 
7.7 consultations per patient-year on average (GP: 5.3; specialists: 2.4). Emergency 
room visits occurred in 10.4% and diagnostic tests included thyroid function (79.1%), 
rectosigmoidoscopy (39.8%) and abdominal echography (36.8%). There were 0.97 IBS-
related admissions to hospital per patient-year. After a second line failure, resource 
use increased with more laxatives (75.5%), antidepressants (24.6%) and pain killers 
(17.3%), 11.6 consultations (GP: 7.5; specialist: 4.1), 14.5% emergency room visits and 
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objeCtives: The IBIS-C study, currently ongoing, is the first to assess the burden 
of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, UK) . We 
present an interim analysis of the retrospective data from Spain. Methods: This is 
an observational, retrospective-prospective (±6-months(m)) study in patients diag-
nosed in the last five years of IBS-C (Rome-III criteria) of moderate-to-severe degree 
(IBS-Symptom Severity Score(IBS-SSS)≥ 175). Quality-of-life(QoL) was assessed 
with the EuroQoL-5D(EQ-5D) and IBS-QoL. Results: We included 46 patients (62% 
severe, mean(±SD) 44.6±12.2 years, 83% women, time since diagnosis 2.8±3.6 years). 
According to IBS-SSS, 94% had abdominal pain in the last month (62% of time) and 
85% abdominal distention. Other prevalent symptoms were: constipation (96%), 
abdominal discomfort (72%) and bloating (59%). Mean IBS-QoL was 46±23, on a scale 
0-100 (worst QoL), and the most affected domains were “food avoidance” (mean:64) 
and “health worry” (60). Mean EQ-5D was 51±20, on a scale 0-100 (best QoL), and 93% 
and 70% of patients, respectively, reported problems in pain/discomfort and anxiety/
depression. In the previous 6m, 83% of patients consulted a primary care physi-
cian, and 89% a specialist (mostly a gastroenterologist)(mean(95%CI):2.8(1.4-4.3) 
and 2.0(0.9-3.1) visits, respectively). 20% of patients required emergency depart-
ment visits or hospitalization (mean stay:1.3(0.6-1.9) days). 76% of patients under-
went a diagnostic test (mean:2.1(1.3-2.9) tests). 89% of patients took medication 
(63% prescription drugs and 54% OTC medications), 26% received complementary 
therapies. The mean direct costs per patient for the National Health System(NHS) 
were € 1,025/6m(549-1627) and the mean costs for the patient were € 200/6m. 17% 
of patients had sick leave(mean:3.5 leaves; mean duration:58 days) and 46% had 
productivity losses(mean:49 hours). Mean indirect costs were € 991/6m. Total costs 
amounted to € 2216/6m. ConClusions: Moderate-to-severe IBS-C has a great 
impact on health care resource utilization and productivity of patients, and the 
results suggest significant costs to the NHS and society. QoL can be severely affected.
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1Inova Fairfax Hospital, Falls Church, VA, USA, 2University of Florida, Gainesvillle, FL, USA, 
3Texas Liver Institute, San Antonio, TX, USA, 4Inova Health System, Falls Church, VA, USA
objeCtives: Interferon-containing regimens for treatment of CH-C are associated 
with substantial side effects and significant impairment in HRQL. The aim of this 
study is to evaluate the effect of Interferon-free regimens on HRQL. Methods: 
Three validated HRQL instruments, namely, Medical Outcomes Study-Short Form 
36 (SF-36), CLDQ-HCV (Chronic Liver Disease Questionnaire-HCV) and FACIT-F 
(Functional Assessment of Chronic Illness Therapy-Fatigue) were administered to 
previously untreated CH-C patients (N= 201) treated with interferon-free regimen 
(Sofosbuvir+Ribavirin) at baseline, during, and after treatment. Patients were ran-
domized to receive 16 weeks of active treatment or 12 weeks of active treatment 
followed by 4 weeks of blinded placebo. Historical data for interferon containing 
regimens were available for all these questionnaires. Results: Small decrements in 
most of the domains of all HRQL metrics were noted at weeks 4, 12, and 16 of active 
treatment regardless of the study arm (maximum observed decrements in HRQL 
summary scores between 3.3% and 8.8% compared to baseline, p< 0.05). There were 
no differences between the study arms at all time points (p> 0.05). These decrements 
were substantially better than historical data available for interferon-containing 
regimens (between 10.4% and 15.2% for the same scores, p< 0.0001). By week 4 of 
follow-up after treatment, some of the social and emotional well-being-related 
domains of FACIT-F improved significantly compared to their own baseline (by 4.9-
6.0%, p< 0.05). At the end of 12-week follow-up, all those domains as well as domains 
of CLDQ-HCV (activity, emotional, worry, systemic domains) further improved (by 
3.8-11.2%, p< 0.05), while physical and functional well-being-related domains of 
FACIT-F and SF-36 returned to their baseline levels or improved moderately (by 3.1-
8.3%, p< 0.05). ConClusions: The impairment in HRQL in CH-C patients treated 
with an interferon-free regimen is minimal and diminishes soon after the end of 
treatment. This interferon-free regimen is associated with substantially better HRQL 
as compared to interferon-containing regimens.
Gastrointestinal DisorDers – health Care use & Policy studies
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objeCtives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The 
objective of this systematic literature review (SLR) was to examine the evidence on 
the efficacy and safety of all available pharmacological interventions for moderate 
to severe UC. Methods: A systematic literature search using a predefined strategy 
was performed in Medline®, EMBASE®, Medline-In-Process, Cochrane Library and 
BIOSIS from 1966 to 2013, to identify randomized controlled trials (RCTs) concern-
ing the efficacy and safety of available treatments in adult patients with moderate 
to severe UC. Studies reporting on mild-moderate UC patients were included if 
they reported results for the moderate subgroup separately. No language restric-
tions were applied to the search. Results: A total of 4344 abstracts were screened 
based on the predefined selection criteria, of which 4279 were excluded. In total, 
65 publications, reporting results from 65 RCTs were included (49 double blind), 
101 patients completed and returned the second package. Both scales had good 
overall fit to Rasch model (Chi2 p = 0.35; Chi2 p = 0.13 for activity limitations and 
QoL respectively) and unidimensionality of the scales was confirmed. No evidence 
of DIF by age or gender was found and the scales had good coverage of the meas-
urement constructs. Internal consistency was 0.91 for the QoL scale and 0.93 for 
Activity limitations. Good reproducibility was observed (QoL 0.91, Activity limita-
tions 0.89) and both scales were able to distinguish between self-perceived disease 
severity and general health status groups (p< .01). ConClusions: The CLIQ is the 
first CD-specific PRO and is truly patient-based as its content was generated directly 
from CD patients. It is well accepted, completed by patients and is easy to score. 
Both scales measure a clear unidimensional construct and generate valid total 
scores. The scales have good consistency, reproducibility and promising construct 
validity. Studies are planned to assess responsiveness. The CLIQ will prove to be an 
important tool for assessing Activity limitations and QoL in clinical audit, practice 
and trials.
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objeCtives: To identify symptoms significantly impacting health-related qual-
ity of life (HRQOL) and how changes in symptoms explain variability in HRQOL 
among adult patients with irritable bowel syndrome with constipation (IBS-
C). Methods: IBS-C symptom and HRQOL data were pooled from two Phase 3 
trials (n= 1602) assessing efficacy and safety of linaclotide, a guanylate cyclase-C 
agonist approved for adult treatment of IBS-C in the US and moderate to severe 
IBS-C in Europe. IBS-C symptoms measured included abdominal (bloating, cramp-
ing, discomfort, fullness, pain) and bowel (spontaneous bowel movement [SBM] 
and complete SBM [CSBM] frequency, stool consistency, and straining) symptoms. 
HRQOL measures included: a disease-specific Irritable Bowel Syndrome-Quality 
of Life questionnaire (IBS-QOL), and generic HRQOL measures, the EuroQol-5D 
(EQ-5D) and Short Form-12 (SF-12). Analysis of variance evaluated relationships 
between Week 12 change from baseline in IBS-C symptoms and HRQOL, con-
trolling for demographics and baseline HRQOL. Results: Changes in IBS-QOL 
overall score were most significantly impacted by changes in abdominal fullness, 
cramping, and straining (beta coefficients: -1.1, -1.3, -1.7, respectively). The full 
model explained nearly half of the changes in IBS-QOL (R-Square: 0.42). Changes 
in EQ-5D were primarily driven by changes in abdominal bloating, cramping, and 
straining (beta coefficients: -0.009, -0.009, -0.011, respectively, R-Square: 0.49). 
Changes in SF-12 physical and mental component summaries (PCS and MCS) 
were best explained by changes in bloating, cramping, and straining (beta coef-
ficients: -0.41, -0.34, -0.53, respectively; R-square: 0.42), and abdominal fullness 
and CSBM frequency (beta coefficients: -0.59 and 0.26, respectively; R-square: 
0.35), respectively. ConClusions: Improvements in abdominal cramping and 
straining at Week 12 compared to baseline were associated with improvements 
in HRQOL as measured by the IBS-QOL, EQ-5D and SF-12 PCS. Improvements in 
abdominal bloating and fullness, and increases in CSBMs were also associated 
with HRQOL improvements. Targeting improvement in specific IBS-C symptoms 
may result in increased patient HRQOL.
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objeCtives: Liver diseases (LDs) have a high impact on morbidity, mortality and 
health-related quality of life (HRQoL). LDs may have different impact on patients’ 
HRQoL. The aim of our study was to evaluate HRQoL in the major liver conditions: 
hepatitis B(HBV), hepatitis C(HCV), cirrhosis(compensated and decompensated), 
hepatocellular carcinoma(HCC), autoimmune hepatitis(AIH), primary biliary 
cirrhosis(PBC), primary sclerosing cholangitis(PSC), NAFLD/NASH, patients in the 
liver transplant list and post-transplant. Methods: A naturalistic, prospective, 
multicenter study has been conducted to generate and validate a set of health care 
outcomes indicators for the major liver conditions. LDs patients (age> 18 years) were 
enrolled in 3 major Italian medical centers and are still being followed up (median 
f-up:13 months). Within this study, socio-demographic, clinical and HRQoL were 
collected using the EQ-5D-3L. The HRQoL data was analyzed dividing the patients 
in sub-groups according to the most recently diagnosed and most severe condi-
tion. Results: We enrolled 3,217 patients, 64.8% male, aged 19-91 (median= 61) 
years; 95.0% of them filled in the EQ-5D at baseline visit. Patients in the HCC group 
were 22.6%; while in the AIH group were 1.6%. The highest percentage of problems 
in Mobility dimension (39.2%) was reported by decompensated cirrhosis sub-group, 
the highest percentage in Self-care (22.6%) and Usual Activities (47.1%) by patients 
in liver transplant list, in Pain/Discomfort (59.2%) by AIH and in Anxiety/Depression 
(57.8%) by PBC. The HBV sub-group reported the best HRQoL with a mean EQ-5D 
VAS of 77.8; while AIH and listed for liver transplant patients reported the worst 
HRQoL levels (mean EQ-5D VAS= 67.7 and 63.5, respectively). ConClusions: our 
study shows how HRQoL is different between LDs and how it is negatively related 
with the clinical severity. Understanding the different impact of LDs on the patients’ 
HRQoL could help physicians and decision makers to better estimate the burden of 
these conditions and to improve the quality of care.
